- Home
- CLPR vs CGTX Comparison
CLPR vs CGTX Comparison
Compare CLPR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | CGTX |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.8M | 94.5M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CLPR | CGTX |
|---|---|---|
| Price | $3.02 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 63.6K | ★ 595.0K |
| Earning Date | 06-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 12.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,997,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.82 | N/A |
| 52 Week Low | $3.02 | $0.22 |
| 52 Week High | $4.61 | $3.83 |
Technical Indicators
Market Signals| Indicator | CLPR | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.99 | 45.35 |
| Support Level | $3.04 | $1.00 |
| Resistance Level | $3.96 | $1.19 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 8.89 | 36.11 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.